KYTX

KYVERNA THERAPEUTICS INC

KYTX·501976104·US·Common Stock·Healthcare - Biotechnology-13D/G

KYTX (KYVERNA THERAPEUTICS INC) is held by 65 institutional investors as of Q1 2026. Largest holders: VANGUARD CAPITAL MANAGEMENT LLC ($15.4M), PRICE T ROWE ASSOCIATES INC /MD/ ($13.4M), BALYASNY ASSET MANAGEMENT L.P. ($9.7M). Net institutional sentiment: Mixed.

65
Holders
Avg rating(12 Elite)
$135.7M
Total Value
61% (68)
Fund Consensus
37 buying - 24 selling
KYTXSmart Money Verdict
View all
Held by 65 funds
12 elite
Who's Trading
ActivistBLBain Capital Life Sciences Opportunities III, LP5.4%Feb 17, 2026
ActivistNVNorthpond Ventures III, LP4.9%Feb 17, 2026
ActivistWBWestlake BioPartners Fund I, L.P. ("Westlake Fund I")6.3%Feb 6, 2026
InsiderSCSEIDENBERG BETH CBuy $1000KDec 18, 2025
InsiderWLWestlake BioPartners Opportunity Fund I, L.P.Buy $1000KDec 18, 2025
InsiderWMWalker Karen MarieSell $293KDec 15, 2025
ActivistGGGordonMD Global Investments LP7.0%Nov 17, 2025
13F: Insider & Congress:
Fund
Action
Shares
Value
Weight
Est. P&L
Conviction
New
1.8M$15.4M0.0%+5.74%
39
Decreased
1.6M(-11.8%)$13.4M0.0%-15.19%
0
Increased
1.1M(+14.7%)$9.7M0.0%-7.62%
32
Increased
1M(+69.5%)$8.7M0.0%-4.43%
41
Decreased
977,289(-2.5%)$8.4M0.0%-1.44%
0
Increased
877,078(+61.1%)$7.6M0.0%+48.63%
40
Increased
845,325(+0.0%)$7.3M0.0%+1.77%
27
Increased
721,581(+39.2%)$6.2M0.0%-5.52%
36
Increased
605,512(+346.5%)$5.2M0.0%+1.95%
44
Increased
577,600(+141.8%)$5M0.0%+21.15%
43
Decreased
500,000(-70.0%)$4.3M0.0%-9.30%
0
Increased
449,750(+122.4%)$3.9M0.0%+19.29%
43
Increased
423,826(+59.1%)$3.7M0.0%-17.50%
38
Increased
412,032(+63.4%)$3.6M0.0%-0.68%
39
Increased
367,492(+106.6%)$3.2M0.0%+40.88%
43
Increased
333,692(+424.5%)$2.9M0.0%+8.91%
42
New
224,584$1.9M0.0%+5.74%
36
Increased
222,929(+592.7%)$1.9M0.0%+13.49%
42
Increased
212,910(+59.5%)$1.8M0.0%+10.41%
37
Increased
211,088(+68.3%)$1.8M0.0%-30.34%
38

Showing 1-20 of 68

1 / 4

Other Healthcare stocks held by institutions

Data sourced from four SEC data sources: 13F, Form 4, 13D/13G, and STOCK Act. Not financial advice. Full disclaimer

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used